Evaluation of non-coding RNAs as potential targets in head and neck squamous cell carcinoma cancer stem cells

Current Drug Targets

Volumn 15, Issue 13, 2014, Pages 1247-1260

  Rahimy, Elham ^a,b,c   Kuo, Selena Z ^a,b   Ongkeko, Weg M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Head and neck squamous cell carcinoma (HNSCC); Long non coding RNA; MicroRNA; Noncoding RNA; PiwiRNA; SnoRNA

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BIOLOGICAL MARKER; CARRIER PROTEINS AND BINDING PROTEINS; CD133 ANTIGEN; CD34 ANTIGEN; GROWTH ARREST SPECIFIC 5 PROTEIN; HERMES ANTIGEN; HOX TRANSCRIPT ANTISENSE INTERGENIC RNA; HYALURONIC ACID; LYMPHOCYTE ANTIGEN; MICRORNA 107; MICRORNA 125B; MICRORNA 200C; MICRORNA 21; MICRORNA 302; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PIWI INTERACTING RNA; PROGRAMMED CELL DEATH 4; PROTEIN P53; RNA H19; SHORT HAIRPIN RNA; SMALL NUCLEOLAR RNA; SOMATOMEDIN B; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ANTINEOPLASTIC AGENT; LONG UNTRANSLATED RNA; MICRORNA; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; DNA DAMAGE; DNA METHYLATION; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOX GENE; HOXD10 GENE; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; RNA, LONG NONCODING; RNA, SMALL INTERFERING; RNA, SMALL NUCLEOLAR; RNA, UNTRANSLATED; SIGNAL TRANSDUCTION;

EID: 84926287544     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141024113446     Document Type: Article

References (189)

1. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110: 1429-35.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994; 73: 187-90.
4. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
5. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
6. Babaie Y, Herwig R, Greber B, et al. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells 2007; 25: 500-10.
7. Chambers I, Silva J, Colby D, et al. Nanog safeguards pluripotency and mediates germline development. Nature 2007; 450: 1230-4.
8. Nowak K, Kerl K, Fehr D, et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006; 34: 1745-54.
9. Dong C, Wilhelm D, Koopman P. Sox genes and cancer. Cytogenet Genome Res 2004; 105: 442-7.
10. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
12. Adikrisna R, Tanaka S, Muramatsu S, et al. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology 2012; 143: 234-45 e7.
13. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
14. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009; 568: 161-73.
15. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Methods Cell Biol 2008; 86: 311-24.
16. Prasetyanti PR, Zimberlin C, De Sousa EMF, Medema JP. Isolation and propagation of colon cancer stem cells. Methods Mol Biol 2013; 1035: 247-59.
17. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-66.
18. Tomuleasa C, Soritau O, Rus-Ciuca D, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis 2010; 19: 61-7.
19. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
20. Chen Y, Zhao J, Luo Y, Wang Y, Wei N, Jiang Y. Isolation and identification of cancer stem-like cells from side population of human prostate cancer cells. J Huazhong Univ Sci Technolog Med Sci 2012; 32: 697-703.
21. Luo Y, Cui XH, Jiang YG, et al. [Sorting and identification of cancer stem cells in human prostate cancer cell lines]. Zhonghua Nan Ke Xue 2012; 18: 1062-8.
22. Luo Y, Lan L, Jiang YG, et al. Epithelial-mesenchymal transition and migration of prostate cancer stem cells is driven by cancerassociated fibroblasts in an HIF-1alpha/beta-catenin-dependent pathway. Mol Cells 2013; 36: 138-44.
23. Sheng X, Li Z, Wang DL, et al. Isolation and enrichment of PC-3 prostate cancer stem-like cells using MACS and serum-free medium. Oncol Lett 2013; 5: 787-92.
24. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-14.
25. Xia H, Yu C, Zhang W, Zhang B, Zhao Y, Fang F. [Identification and isolation of cancer stem cells from a549 cells]. Zhongguo Fei Ai Za Zhi 2013; 16: 400-4.
26. Gomez-Casal R, Bhattacharya C, Ganesh N, et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer 2013; 12: 94.
27. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-8.
28. Kuo SZ, Blair KJ, Rahimy E, et al. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer 2012; 12: 556.
29. Major AG, Pitty LP, Farah CS. Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int 2013; 2013: 319489.
30. Abhold EL, Kiang A, Rahimy E, et al. EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS One 2012; 7: e32459.
31. Clay MR, Tabor M, Owen JH, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010; 32: 1195-201.
32. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012; 287: 32800-24.
33. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLLAF9. Nature 2006; 442: 818-22.
34. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6: 587-96.
35. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355: 1253-61.
36. Hu YK, Wang X, Li L, Du YH, Ye HT, Li CY. MicroRNA-98 induces an Alzheimer's disease-like disturbance by targeting insulin-like growth factor 1. Neurosci Bull 2013; 29: 745-51.
37. Omran A, Elimam D, Yin F. MicroRNAs: New Insights into Chronic Childhood Diseases. Biomed Res Int 2013; 2013: 291826.
38. Heymans S, Corsten MF, Verhesen W, et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013; 128: 1420-32.
39. Schonrock N, Matamales M, Ittner LM, Gotz J. MicroRNA networks surrounding APP and amyloid-beta metabolism--implications for Alzheimer's disease. Exp Neurol 2012; 235: 447-54.
40. Aranda JF, Madrigal-Matute J, Rotllan N, Fernandez-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med 2013; 64: 31-9.
41. Cui Z, Ren S, Lu J, et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol 2013; 31: 1117-23.
42. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol 2011; 21: 354-61.
43. Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011; 54: 1679-89.
44. Dong XY, Guo P, Boyd J, et al. Implication of snoRNA U50 in human breast cancer. J Genet Genomics 2009; 36: 447-54.
45. Peters J. Prader-Willi and snoRNAs. Nat Genet 2008; 40: 688-9.
46. Heyn H, Ferreira HJ, Bassas L, et al. Epigenetic disruption of the PIWI pathway in human spermatogenic disorders. PLoS One 2012; 7: e47892.
47. Wang Q, Wei L, Guan X, Wu Y, Zou Q, Ji Z. Briefing in family characteristics of microRNAs and their applications in cancer research. Biochim Biophys Acta 2014; 1844: 191-7.
48. Zhao RC, Zhu YS, Shi Y. New hope for cancer treatment: exploring the distinction between normal adult stem cells and cancer stem cells. Pharmacol Ther 2008; 119: 74-82.
49. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-74.
50. Kaikkonen MU, Lam MT, Glass CK. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res 2011; 90: 430-40.
51. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-71.
52. Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: function, detection, and bioanalysis. Chem Rev 2013; 113: 6207-33.
53. Lu L, Katsaros D, Zhu Y, et al. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Res Treat 2011; 126: 687-94.
54. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008; 455: 1124-8.
55. Lee I, Ajay SS, Yook JI, et al. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res 2009; 19: 1175-83.
56. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
57. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
58. Lowery AJ, Miller N, McNeill RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008; 14: 360-5.
59. Lin PY, Yang PC. Circulating miRNA signature for early diagnosis of lung cancer. EMBO Mol Med 2011; 3: 436-7.
60. Howard JD, Cheng H, Perez J, et al. miRNA array analysis determines miR-205 is overexpressed in head and neck squamous cell carcinoma and enhances cellular proliferation. Cancer Res Ther 2013; 1: 153-62.
61. Ramdas L, Giri U, Ashorn CL, et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 2009; 31: 642-54.
62. Gomes CC, Gomez RS. MicroRNA and oral cancer: future perspectives. Oral Oncol 2008; 44: 910-4.
63. Wang Y, Blelloch R. Cell cycle regulation by microRNAs in stem cells. Results Probl Cell Differ 2011; 53: 459-72.
64. Wang Y, Blelloch R. Cell cycle regulation by MicroRNAs in embryonic stem cells. Cancer Res 2009; 69: 4093-6.
65. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007; 6: 2127-32.
66. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011; 38: 724-33.
67. Jovanovic M, Hengartner MO. miRNAs and apoptosis: RNAs to die for. Oncogene 2006; 25: 6176-87.
68. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009; 10: 116-25.
69. Ren J, Jin P, Wang E, Marincola FM, Stroncek DF. MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med 2009; 7: 20.
70. Suh MR, Lee Y, Kim JY, et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol 2004; 270: 488-98.
71. Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet 2003; 35: 215-7.
72. DeSano JT, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. Aaps J 2009; 11: 682-92.
73. Ji Q, Karnak D, Hao P, Wang R, Xu L. No small matter: microRNAs-key regulators of cancer stem cells. Int J Clin Exp Med 2010; 3: 84-7.
74. Chen C, Zimmermann M, Tinhofer I, Kaufmann AM, Albers AE. Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Lett 2013; 338: 47-56.
75. Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. Rna 2008; 14: 2115-24.
76. Card DA, Hebbar PB, Li L, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol 2008; 28: 6426-38.
77. Liu H, Deng S, Zhao Z, et al. Oct4 regulates the miR-302 cluster in P19 mouse embryonic carcinoma cells. Mol Biol Rep 2011; 38: 2155-60.
78. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010; 17: F19-36.
79. Childs G, Fazzari M, Kung G, et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 2009; 174: 736-45.
80. Yu CC, Chen YW, Chiou GY, et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol 2011; 47: 202-10.
81. Alajez NM, Shi W, Wong D, et al. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget 2012; 3: 1641-52.
82. Yang X, Lin X, Zhong X, et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 2010; 70: 9463-72.
83. Nakanishi H, Taccioli C, Palatini J, et al. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 2014; 33: 702-12.
84. Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E, Gollin SM. Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 2009; 48: 569-82.
85. Liang L, Wong CM, Ying Q, et al. MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 2010; 52: 1731-40.
86. Wu L, Belasco JG. Micro-RNA regulation of the mammalian lin-28 gene during neuronal differentiation of embryonal carcinoma cells. Mol Cell Biol 2005; 25: 9198-208.
87. Zhong X, Li N, Liang S, Huang Q, Coukos G, Zhang L. Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem 2010; 285: 41961-71.
88. Wang J, Cao N, Yuan M, et al. MicroRNA-125b/Lin28 pathway contributes to the mesendodermal fate decision of embryonic stem cells. Stem Cells Dev 2012; 21: 1524-37.
89. Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stemcell commitment. Nat Cell Biol 2008; 10: 987-93.
90. Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 2013; 6: 6.
91. Liu Z, Liu H, Desai S, et al. miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. J Biol Chem 2013; 288: 4334-45.
92. Chen LH, Tsai KL, Chen YW, et al. MicroRNA as a Novel Modulator in Head and Neck Squamous Carcinoma. J Oncol 2010; 2010: 135632.
93. Lo WL, Yu CC, Chiou GY, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol 2011; 223: 482-95.
94. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
95. Chen YC, Chang CJ, Hsu HS, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol 2010; 46: 158-65.
96. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094-105.
97. Datta J, Smith A, Lang JC, et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cvarepsilon. Oncogene 2012; 31: 4045-53.
98. Chen L, Chen XR, Chen FF, et al. MicroRNA-107 inhibits U87 glioma stem cells growth and invasion. Cell Mol Neurobiol 2013; 33: 651-7.
99. Xie X, Piao L, Cavey GS, et al. Phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis. Oncogene 2014; 33: 2040-52.
100. [100] Avissar M, McClean MD, Kelsey KT, Marsit CJ. MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 2009; 30: 2059-63.
101. [101] Li J, Huang H, Sun L, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009; 15: 3998-4008.
102. [102] Huo JS, Zambidis ET. Pivots of pluripotency: the roles of noncoding RNA in regulating embryonic and induced pluripotent stem cells. Biochim Biophys Acta 2013; 1830: 2385-94.
103. [103] Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23: 1494-504.
104. [104] Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43: 904-14.
105. [105] Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629-41.
106. [106] Karapetyan AR, Buiting C, Kuiper RA, Coolen MW. Regulatory Roles for Long ncRNA and mRNA. Cancers 2013; 5: 462-90.
107. [107] Torarinsson E, Sawera M, Havgaard JH, Fredholm M, Gorodkin J. Thousands of corresponding human and mouse genomic regions unalignable in primary sequence contain common RNA structure. Genome Res 2006; 16: 885-9.
108. [108] Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 2011; 71: 3-7.
109. [109] Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011; 6: 1984-92.
110. [110] Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18: 1243-50.
111. [111] Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458: 223-7.
112. [112] Dinger ME, Amaral PP, Mercer TR, et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res 2008; 18: 1433-45.
113. [113] Gibb EA, Brown CJ, Lam WL. The functional role of long noncoding RNA in human carcinomas. Mol Cancer 2011; 10: 38.
114. [114] Gibb EA, Vucic EA, Enfield KS, et al. Human cancer long noncoding RNA transcriptomes. PLoS One 2011; 6: e25915.
115. [115] Gibb EA, Enfield KS, Stewart GL, et al. Long non-coding RNAs are expressed in oral mucosa and altered in oral premalignant lesions. Oral Oncol 2011; 47: 1055-61.
116. [116] Tang H, Wu Z, Zhang J, Su B. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep 2013; 7: 761-6.
117. [117] Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 2011; 477: 295-300.
118. [118] Sheik Mohamed J, Gaughwin PM, Lim B, Robson P, Lipovich L. Conserved long noncoding RNAs transcriptionally regulated by Oct4 and Nanog modulate pluripotency in mouse embryonic stem cells. RNA 2010; 16: 324-37.
119. [119] Hawkins PG, Morris KV. Transcriptional regulation of Oct4 by a long non-coding RNA antisense to Oct4-pseudogene 5. Transcription 2010; 1: 165-75.
120. [120] Anguera MC, Sadreyev R, Zhang Z, et al. Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. Cell Stem Cell 2012; 11: 75-90.
121. [121] Rainho CA, Kowalski LP, Rogatto SR. Loss of imprinting and loss of heterozygosity on 11p15.5 in head and neck squamous cell carcinomas. Head Neck 2001; 23: 851-9.
122. [122] Ratajczak MZ. Igf2-H19, an imprinted tandem gene, is an important regulator of embryonic development, a guardian of proliferation of adult pluripotent stem cells, a regulator of longevity, and a 'passkey' to cancerogenesis. Folia Histochem Cytobiol 2012; 50: 171-9.
123. [123] Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. Tumoursuppressor activity of H19 RNA. Nature 1993; 365: 764-7.
124. [124] Venkatraman A, He XC, Thorvaldsen JL, et al. Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature 2013; 500: 345-9.
125. [125] Matouk IJ, DeGroot N, Mezan S, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007; 2: e845.
126. [126] Berteaux N, Lottin S, Monte D, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem 2005; 280: 29625-36.
127. [127] Nie Y, Liu X, Qu S, Song E, Zou H, Gong C. Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival. Cancer Sci 2013; 104: 458-64.
128. [128] Li D, Feng J, Wu T, et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol 2013; 182: 64-70.
129. [129] Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71: 6320-6.
130. [130] Schorderet P, Duboule D. Structural and functional differences in the long non-coding RNA hotair in mouse and human. PLoS Genet 2011; 7: e1002071.
131. [131] Hakami F, Darda L, Stafford P, Woll P, Lambert DW, Hunter KD. The roles of HOXD10 in the development and progression of head and neck squamous cell carcinoma (HNSCC). Br J Cancer 2014; 111: 807-16.
132. [132] Hunter KD, Thurlow JK, Fleming J, et al. Divergent routes to oral cancer. Cancer Res 2006; 66: 7405-13.
133. [133] Siomi MC, Sato K, Pezic D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Biol 2011; 12: 246-58.
134. [134] Thomson T, Lin H. The biogenesis and function of PIWI proteins and piRNAs: progress and prospect. Annu Rev Cell Dev Biol 2009; 25: 355-76.
135. [135] Suzuki R, Honda S, Kirino Y. PIWI Expression and Function in Cancer. Frontiers in genetics 2012; 3: 204.
136. [136] Siomi MC, Sato K, Pezic D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defence. Nature reviews Molecular cell biology 2011; 12: 246-58.
137. [137] Juliano C, Wang J, Lin H. Uniting germline and stem cells: the function of Piwi proteins and the piRNA pathway in diverse organisms. Annual review of genetics 2011; 45: 447-69.
138. [138] Bamezai S, Rawat VP, Buske C. Concise review: The Piwi-piRNA axis: pivotal beyond transposon silencing. Stem Cells 2012; 30: 2603-11.
139. [139] Aravin A, Gaidatzis D, Pfeffer S, et al. A novel class of small RNAs bind to MILI protein in mouse testes. Nature 2006; 442: 203-7.
140. [140] Grivna ST, Beyret E, Wang Z, Lin H. A novel class of small RNAs in mouse spermatogenic cells. Genes Dev 2006; 20: 1709-14.
141. [141] Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 2006; 442: 199-202.
142. [142] Sharma AK, Nelson MC, Brandt JE, et al. Human CD34(+) stem cells express the hiwi gene, a human homologue of the Drosophila gene piwi. Blood 2001; 97: 426-34.
143. [143] Kim VN. Small RNAs just got bigger: Piwi-interacting RNAs (piRNAs) in mammalian testes. Genes Dev 2006; 20: 1993-7.
144. [144] Rouget C, Papin C, Boureux A, et al. Maternal mRNA deadenylation and decay by the piRNA pathway in the early Drosophila embryo. Nature 2010; 467: 1128-32.
145. [145] Cheng J, Deng H, Xiao B, et al. piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells. Cancer Lett 2012; 315: 12-7.
146. [146] Cheng J, Guo JM, Xiao BX, et al. piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. Clin Chim Acta 2011; 412: 1621-5.
147. [147] Cui L, Lou Y, Zhang X, et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using piRNAs as markers. Clin Biochem 2011; 44: 1050-7.
148. [148] Qiao D, Zeeman AM, Deng W, Looijenga LH, Lin H. Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas. Oncogene 2002; 21: 3988-99.
149. [149] Suzuki R, Honda S, Kirino Y. PIWI Expression and Function in Cancer. Front Genet 2012; 3: 204.
150. [150] Taubert H, Greither T, Kaushal D, et al. Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma. Oncogene 2007; 26: 1098-100.
151. [151] Siddiqi S, Matushansky I. Piwis and piwi-interacting RNAs in the epigenetics of cancer. J Cell Biochem 2012; 113: 373-80.
152. [152] Liu WK, Jiang XY, Zhang ZX. Expression of PSCA, PIWIL1 and TBX2 and its correlation with HPV16 infection in formalin-fixed, paraffin-embedded cervical squamous cell carcinoma specimens. Arch Virol 2010; 155: 657-63.
153. [153] Zhao YM, Zhou JM, Wang LR, et al. HIWI is associated with prognosis in patients with hepatocellular carcinoma after curative resection. Cancer 2012; 118: 2708-17.
154. [154] Wang Y, Liu Y, Shen X, et al. The PIWI protein acts as a predictive marker for human gastric cancer. Int J Clin Exp Pathol 2012; 5: 315-25.
155. [155] Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-9.
156. [156] Lu Y, Zhang K, Li C, et al. Piwil2 suppresses p53 by inducing phosphorylation of signal transducer and activator of transcription 3 in tumor cells. PLoS One 2012; 7: e30999.
157. [157] He W, Wang Z, Wang Q, et al. Expression of HIWI in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. BMC Cancer 2009; 9: 426.
158. [158] Liu WK, Jiang XY, Zhang ZX. Expression of PSCA, PIWIL1 and TBX2 and its correlation with HPV16 infection in formalin-fixed, paraffin-embedded cervical squamous cell carcinoma specimens. Arch Virol 2010; 155: 657-63.
159. [159] Siddiqi S, Terry M, Matushansky I. Hiwi mediated tumorigenesis is associated with DNA hypermethylation. PloS one 2012; 7: e33711.
160. [160] Liang D, Fang Z, Dong M, et al. Effect of RNA interferencerelated HiWi gene expression on the proliferation and apoptosis of lung cancer stem cells. Oncology letters 2012; 4: 146-50.
161. [161] Klenov MS, Sokolova OA, Yakushev EY, et al. Separation of stem cell maintenance and transposon silencing functions of Piwi protein. Proc Natl Acad Sci USA 2011; 108: 18760-5.
162. [162] Juliano C, Wang J, Lin H. Uniting germline and stem cells: the function of Piwi proteins and the piRNA pathway in diverse organisms. Annu Rev Genet 2011; 45: 447-69.
163. [163] Klattenhoff C, Theurkauf W. Biogenesis and germline functions of piRNAs. Development 2008; 135: 3-9.
164. [164] Bachellerie JP, Cavaille J, Huttenhofer A. The expanding snoRNA world. Biochimie 2002; 84: 775-90.
165. [165] Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer 2012; 12: 84-8.
166. [166] Saraiya AA, Wang CC. snoRNA, a novel precursor of microRNA in Giardia lamblia. PLoS Pathog 2008; 4: e1000224.
167. [167] Soeno Y, Taya Y, Stasyk T, Huber LA, Aoba T, Huttenhofer A. Identification of novel ribonucleo-protein complexes from the brain-specific snoRNA MBII-52. Rna 2010; 16: 1293-300.
168. [168] Ender C, Krek A, Friedlander MR, et al. A human snoRNA with microRNA-like functions. Mol Cell 2008; 32: 519-28.
169. [169] Sridhar P, Gan HH, Schlick T. A computational screen for C/D box snoRNAs in the human genomic region associated with Prader-Willi and Angelman syndromes. J Biomed Sci 2008; 15: 697-705.
170. [170] Liao J, Yu L, Mei Y, et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer 2010; 9: 198.
171. [171] Mei YP, Liao JP, Shen J, et al. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene 2012; 31: 2794-804.
172. [172] Gee HE, Buffa FM, Camps C, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 2011; 104: 1168-77.
173. [173] Tanaka R, Satoh H, Moriyama M, et al. Intronic U50 smallnucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. Genes Cells 2000; 5: 277-87.
174. [174] Dong XY, Rodriguez C, Guo P, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet 2008; 17: 1031-42.
175. [175] Su H, Xu T, Ganapathy S, et al. Elevated snoRNA biogenesis is essential in breast cancer. Oncogene 2014; 33: 1348-58.
176. [176] Smith CM, Steitz JA. Classification of gas5 as a multi-smallnucleolar-RNA (snoRNA) host gene and a member of the 5'-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. Mol Cell Biol 1998; 18: 6897-909.
177. [177] Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest-and starvation-associated repressor of the glucocorticoid receptor. Sci Signal 2010; 3: ra8.
178. [178] Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28: 195-208.
179. [179] Player A, Wang Y, Bhattacharya B, Rao M, Puri RK, Kawasaki ES. Comparisons between transcriptional regulation and RNA expression in human embryonic stem cell lines. Stem Cells Dev 2006; 15: 315-23.
180. [180] Zhang Z, Zhu Z, Watabe K, et al. Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ 2013; 20: 1558-68.
181. [181] Jalali S, Bhartiya D, Lalwani MK, Sivasubbu S, Scaria V. Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS One 2013; 8: e53823.
182. [182] Cesana M, Cacchiarelli D, Legnini I, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011; 147: 358-69.
183. [183] Taulli R, Pandolfi PP. “Snorkeling” for missing players in cancer. J Clin Invest 2012; 122: 2765-8.
184. [184] Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10: 57-63.
185. [185] Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 2010; 15: 355-73.
186. [186] Takes RP, Baatenburg de Jong RJ, Schuuring E, Litvinov SV, Hermans J, Van Krieken JH. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 1998; 18: 4793-800.
187. [187] Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009; 4: 49-70.
188. [188] Thibaudeau E, Fortin B, Coutlee F, et al. HPV Prevalence and Prognostic Value in a Prospective Cohort of 255 Patients with Locally Advanced HNSCC: A Single-Centre Experience. Int J Otolaryngol 2013; 2013: 437815.
189. [189] Lajer CB, Nielsen FC, Friis-Hansen L, et al. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer 2011; 104: 830-40.